Full-Year 2024 guidance has cost realignment program involving undisclosed layoffs now expected to deliver annual cost savings of at least $4.0 billion.
Thermo Fisher to identify local labs that will be using its NGS technology and Pfizer will explore ways to enable affordable patient access for NGS testing.
Seagen’s portfolio includes four approved medicines across solid tumors and hematologic malignancies, including three ADCs: ADCETRIS, PADCEV, and TIVDAK.